Page Content
Featured
Off
Source
McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. Published online March 29, 2025. doi:10.1056/NEJMoa2501006
Thumbnail
Speciality
Currency
Sub Speciality
Sub Sub Speciality
Short Description
SOUL Trial assessed the cardiovascular efficacy of oral semaglutide in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease, chronic kidney disease, or both.
User Segments
Release Date
Featured Order
0
Is Paid
0